TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioAge Labs, Inc. ( (BIOA) ) just unveiled an announcement.
On December 4, 2025, BioAge Labs announced positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel NLRP3 inhibitor. The trial showed that BGE-102 was well-tolerated and achieved significant suppression of IL-1β, indicating strong target engagement and high brain penetration. The company plans to expand the trial to include participants with obesity and elevated hsCRP, with further data expected in the first half of 2026. These findings support BGE-102’s potential to target inflammation in both the central nervous system and peripheral tissues, positioning BioAge favorably in the biopharmaceutical industry.
The most recent analyst rating on (BIOA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.
Spark’s Take on BIOA Stock
According to Spark, TipRanks’ AI Analyst, BIOA is a Underperform.
BioAge Labs, Inc. is facing critical financial difficulties, characterized by no revenue generation, increasing losses, and dependence on external financing. The technical indicators suggest a bearish trend, and the lack of valuation metrics such as P/E ratio and dividend yield complicates valuation. These factors collectively reflect a weak overall stock performance.
To see Spark’s full report on BIOA stock, click here.
More about BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity and cardiovascular risk factors.
Average Trading Volume: 351,202
Technical Sentiment Signal: Strong Buy
Current Market Cap: $304.4M
See more data about BIOA stock on TipRanks’ Stock Analysis page.